RIPK3 and cancer: HS-1371 is a kinase inhibitor that has a potential use for kinase-dependent cell death, but in our study, we identified this compound as a new potent RIP3 inhibitor, thereby highlighting the risk of misinterpretation when developing drugs as selective kinase inhibitors in cancer therapy40.